Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Francis P. Worden, MD, on Vismodegib: Organ Preservation for Orbital/Periocular Basal Cell Carcinoma

Posted: Monday, July 13, 2020

Francis P. Worden, MD, of the University of Michigan Health System Comprehensive Cancer Center, discusses vismodegib as a potentially practice-changing neoadjuvant treatment for patients with locally advanced periocular basal cell carcinoma of the eye and lacrimal drainage system, in which surgery would result in unacceptable morbidity.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.